Select Medical upgraded at RW Baird As reported previously, Baird upgraded Select Medical to Overweight from Neutral. The firm sees a measurable reimbursement headwind as the company has the highest compliant mix of any LTAC chain, expectations for improved pricing, and expectations for the company's earnings are low. Price target raised to $15 from $10.
Select Medical downgraded to Sell from Neutral at UBS UBS downgraded Select Medical Holdings to Sell citing uncertainty following the company's plans to push out its transition from the current payment methodology. It keeps a $15 price target for shares.